Randomized Trial for Botox Urinary Incontinence: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Randomized Trial for Botox Urinary Incontinence (NCT00178191), a randomized na study. The primary outcome is Episodes/Day.

2. Clinical Question

The registry reports an enrollment of 28. That figure describes the trial’s enrollment, while the outcome summaries list the numbers contributing to each arm’s reported result. The record does not explain the relationship between those numbers, such as whether all enrolled participants contributed to the outcome. Further details about the target population, eligibility criteria, treatment delivery, and follow-up procedures are not reported in the registry record.

3. Trial Design

The registry describes a randomized, double-masked, parallel trial with three groups: 200 units of Botox, 300 units of Botox, and placebo. Randomization is intended to allocate participants to study groups by chance, while masking is intended to limit the influence of treatment knowledge on participants or study personnel. The record labels the masking as double but does not identify which individuals were masked or how masking was maintained. It also does not give details of the randomization sequence or allocation concealment.

The total enrollment is 28. The posted arm-level outcome summaries list 11 participants for 200 units, 10 for 300 units, and 7 for placebo. These are the group sizes associated with the posted means and standard errors; the registry does not explain whether these are randomized, treated, or analyzed populations, nor does it report reasons for any difference between enrollment and outcome counts.

The trial is marked completed. Its recorded start is 2005-06, and its primary completion is 2008-07. The primary outcome timeframe is 9 months. No additional detail about the timing or frequency of assessments is reported in the registry record. The phase is listed as NA. The sponsor is the University of Rochester.

Bladder diaries, questionnaires, urodynamics, and pad weight are listed among the interventions or procedures. The record does not provide enough detail to establish how each was used, what procedures participants underwent, or how these measurements related to treatment administration. The posted results contain one outcome measure and no posted analyses. The trial’s protocol, statistical analysis plan, and fuller operational details are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Episodes/Day, measured over 9 months.

The primary endpoint is the number of incontinence episodes per day, assessed at 9 months. It is a continuous measure: each participant’s episode count is summarized as a group mean. The endpoint directly reflects the frequency of the symptom the study set out to examine. A daily count can help describe how often leakage episodes occurred during the assessment period, while an arm-level mean provides a concise summary for each group.

The registry reports the outcome as a mean with a standard error. A mean describes the central level of the recorded measure across participants in a group. A standard error describes the uncertainty around the estimated group mean; it is not a direct summary of how much participants’ individual episode counts varied. The posted record does not give individual observations or another measure of participant-to-participant variation.

The timeframe matters when interpreting the figures: the reported endpoint is at 9 months, not an account of change over time. The registry does not post a baseline value alongside the outcome or a change-from-baseline analysis. It also does not state in the posted outcome description how episode counts were collected, how days with missing diary entries were handled, or how the assessment window was defined. Those details are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry classifies the primary endpoint as continuous and reports a mean with a standard error for each arm. These summaries answer a descriptive question: what was the average daily episode count recorded for the participants represented in each group’s outcome summary? They do not, on their own, answer the comparative question of how much one treatment group differed from another.

What does the mean describe?

A mean combines participant-level values into a single group summary. For a count of incontinence episodes per day, it represents the average number of episodes across the participants included in that group’s reported outcome. It does not imply that every participant had a value close to the mean. Participants may have had very different episode counts, and the mean alone does not reveal that distribution.

Means can be useful for comparing groups when the outcome is measured consistently and an appropriate analysis is performed. A comparison generally estimates a contrast, such as the difference between group means, and quantifies uncertainty in that contrast. The registry does not post such a contrast for this endpoint. No new comparison should be inferred from the separate arm summaries alone.

What does the standard error describe?

The standard error describes the precision of an estimated mean. In general, it reflects how much the estimate might vary across repeated samples under a statistical model. It is not the same as the standard deviation, which describes variation among individual observations. A standard error can be used in constructing an interval estimate for a mean when the relevant assumptions and analysis are specified. However, an arm-specific standard error is not itself an interval for the treatment effect between two groups.

For a comparative question, uncertainty depends on the estimated contrast and its standard error, with the analysis reflecting the study design and any relevant modeling decisions. The posted record does not give a contrast, a contrast standard error, or a confidence interval. It also does not identify an analysis method from which those quantities could be recovered. Consequently, the arm-level standard errors should be interpreted only as precision summaries for the posted means.

Why does randomization matter?

Random allocation is a design feature intended to make treatment groups comparable, on average, with respect to factors present before assignment. It supports a causal interpretation of a properly conducted and analyzed trial, but it does not remove sampling uncertainty. The trial’s randomized label does not by itself provide the missing comparative estimate or show how the randomization was implemented. Details about sequence generation, concealment, and any departures from assigned treatment are not reported in the registry record.

Masking can reduce some kinds of bias, such as influence from expectations when outcomes are assessed or reported. The registry labels the trial double-masked, but does not specify who was masked, whether masking remained intact, or how it was maintained. The primary endpoint involves episodes recorded by participants, and the record does not describe the diary procedure or assessment process in enough detail to assess these issues further.

What can be concluded from the posted analysis information?

The registry lists one outcome measure and zero posted analyses. The outcome summary supplies an estimate for each arm, but no formal between-group test, model, adjusted estimate, or confidence interval. It therefore does not report whether any comparative analysis accounted for baseline values, other covariates, or the trial’s allocation structure. Those analysis choices are not reported in the registry record, so it would be inappropriate to infer them.

A p-value, if reported for a well-defined comparison, would describe how compatible the observed data are with a specified null hypothesis under the assumptions of the test. It would not measure the size or clinical importance of an effect. No p-value for a comparison is posted for this endpoint. A confidence interval would communicate a range of effect estimates compatible with the data and analysis assumptions; no interval for a treatment contrast is reported either.

Why might distributional details matter?

Episode counts are count data, even when summarized by a mean. General statistical methods for count outcomes may need to account for features such as skewness, many low or zero values, or over-dispersion, meaning that participant-level variation exceeds what a simple model assumes. These are general considerations, not claims about the distribution in this trial. The registry does not post participant-level values or a distributional assessment, so it is not possible to determine whether any particular feature was present or which model would have been appropriate.

Likewise, a normal approximation may be used in some settings to estimate uncertainty, but its suitability depends on the data and analysis. The registry does not report a model for the primary outcome. No distributional assumption or model should be attributed to the trial on the basis of the arm-level means and standard errors alone.

What does the planning information mean?

The registry record includes assumptions for a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. Such an illustration is not an observed trial result and does not describe the trial’s original design justification. The record does not report the trial’s sample-size rationale. Further, because the comparative values needed for this continuous endpoint are missing, the registry identifies the two-arm comparison as not estimable. No specific planning sample size can be interpreted from the posted comparison results.

In general, planning calculations depend on assumptions about the effect to detect, variability, significance level, allocation, and analysis. They are prospective illustrations under those assumptions, not evidence that a study had a particular probability of finding an effect after it was conducted. A planning illustration must not be confused with an observed treatment effect or with an analysis of the completed trial.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("200 Units Botox", "300 Units Botox", "Placebo")
n   <- c(11, 10, 7)
m   <- c(6.6, 3.52, 8.7)
sp  <- c(0.9687, 0.95, 1.52)
sd  <- sp * sqrt(n)      # standard errors converted to SDs
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  200 Units Botox  11  6.600  3.213  4.442  8.758
CARM  300 Units Botox  10  3.520  3.004  1.371  5.669
CARM  Placebo  7  8.700  4.022  4.981  12.419

11. Multiplicity, Missing Data and Analysis Populations

The registry posts one outcome measure, the number of incontinence episodes per day at 9 months, and no secondary posted outcomes. This limits what can be assessed about multiplicity from the record: there is no set of posted outcome tests on which to evaluate a multiplicity adjustment. The registry does not report whether the protocol included other outcomes or whether any planned outcomes were omitted, nor does it report a multiplicity procedure. These details are not reported in the registry record.

No analysis is posted for the primary outcome. The record therefore does not identify an analysis population, such as all randomized participants or participants with an observed endpoint, and does not describe how participants were handled if they did not complete follow-up. Although the arm-level summaries list participant counts, those counts alone do not establish the population definition or the handling of missing outcome values.

Missing-data methods can affect estimates when participants lack outcome measurements. General approaches include analyzing observed values under specified assumptions, using imputation models, or conducting sensitivity analyses. The appropriateness of an approach depends on why data are missing and on the analysis plan. The registry does not report the amount or pattern of missingness, reasons for missing data, imputation, or sensitivity analyses. None should be assumed.

The record also does not report whether interim analyses were planned or conducted, or whether the analysis plan changed. The posted arm-level results are therefore insufficient to determine how outcome selection, missing data, or multiple looks at the data were addressed. These are uncertainties about the available record, not evidence that any particular procedure was or was not used in the full trial.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry reports zero participants with serious adverse events in the 200-unit Botox group, zero in the 300-unit group, and zero in the placebo group. The corresponding numbers at risk are 11, 10, and 7. The record also lists zero participants with other adverse events in each group, using the same group sizes. No serious adverse event terms are listed.

These figures describe what is recorded in the registry; they should not be read as proof that no adverse events of any kind occurred. The safety summary reports counts for the specified categories, and the record does not provide additional detail about event definitions, collection methods, severity grading, or follow-up completeness. Death counts are not reported in the registry record.

Zero recorded events in a group means that the registry lists no participants with an event in that category for that group. It does not show that the underlying risk is zero, particularly when the group sizes are small. The summaries also do not provide a comparative safety analysis or uncertainty estimates for differences between groups. No conclusion about relative safety can be drawn from these counts alone.

13. What the Result Does, and Does Not, Mean

The posted results describe the mean number of incontinence episodes per day at 9 months for each of the three groups. They also report a standard error and an outcome count for each arm. This is useful descriptive information about the observed trial groups, but it is not a complete statistical evaluation of the study’s primary question.

The results do not provide an estimated difference between either Botox dose and placebo, a confidence interval for a treatment contrast, or a p-value. As a result, the registry does not show the magnitude and precision of any comparative effect. The listed group means have a visible ordering, but that ordering by itself cannot distinguish a treatment-related difference from chance variation. It also cannot establish whether a difference is meaningful to participants.

The registry describes the purpose as examining reduction in leakage and comparing dose effectiveness and safety. The primary posted endpoint addresses daily episode frequency at 9 months; it does not by itself summarize every aspect of leakage, safety, or participant experience. Although diaries, questionnaires, urodynamics, and pad weight are listed, the record does not post results for additional measures. It therefore cannot support conclusions about outcomes that are not reported.

The safety counts are limited to the adverse-event categories recorded in the registry. Zero reported events in each group does not establish an absence of risk, and the group sizes are limited. Deaths are not reported in the registry record. The absence of a posted comparative safety analysis further limits interpretation across groups.

These results should be understood as a registry-level account rather than a full report of all trial methods and analyses. Details about the protocol, analysis plan, missing data, and participant-level outcome distributions are not reported in the registry record. Without those details and without inferential comparisons, the posted summaries cannot establish the certainty, robustness, or broader applicability of a treatment effect. They describe what was recorded for the study groups at the stated assessment time, and no more.

14. Why This Trial Matters Statistically

This trial is statistically instructive because it illustrates the difference between reporting group summaries and reporting a treatment comparison. Means and standard errors convey information about each arm’s observed outcome, but the central question in a randomized trial is usually comparative. A direct estimate of the contrast, accompanied by an uncertainty measure, is needed to assess both the size and precision of that comparison.

The distinction is particularly important when the outcome is continuous and the registry gives only arm-level summaries. A reader may be tempted to compare the means informally, yet that does not account for uncertainty in the contrast. The standard error for each mean is not a substitute for the standard error of the difference. Here, the registry explicitly does not provide the values needed for a two-arm comparison of the continuous endpoint.

The small arm-level counts also reinforce why precision matters. A group mean is an estimate based on the participants represented in that group’s summary; it is not a fixed quantity that can be treated as exact. Without a confidence interval or an analysis, readers cannot judge how much uncertainty accompanies a comparison or how sensitive it might be to individual observations.

The case also shows why registry completeness matters. Information about analysis populations, missing outcome data, multiplicity, and model choice can shape interpretation, but those details are not reported. The record’s safety counts are likewise descriptive, not a comparative safety assessment. These limitations do not erase the posted data; they define what the data can support. Statistically, the key lesson is to distinguish an observed arm-level pattern from an analyzed and quantified treatment effect.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation of the registry results is the absence of a posted comparative analysis for the primary endpoint. The record gives arm-level means and standard errors, but no estimated contrast, confidence interval, or p-value. It also states that values needed for a two-arm comparison of this continuous outcome are missing or not estimable. The displayed summaries therefore cannot establish the size or precision of a treatment difference.

The outcome summaries are tied to 9 months and do not include a posted baseline measure or change-from-baseline estimate. The registry does not describe the diary collection procedure, assessment window, or handling of missing diary entries. These omissions make it difficult to understand exactly how daily episode counts were assembled and whether all participants contributed comparable measurements.

The enrollment is 28, while the reported outcome groups list 11, 10, and 7 participants. The registry does not explain the analysis population or provide reasons for the counts associated with the endpoint. It does not report missing-data methods, exclusions, adherence, or sensitivity analyses. Participant-level distributions are also absent, so the spread and shape of the outcome cannot be assessed from the posted summaries.

Further trial details are not reported in the registry record, including eligibility criteria, randomization implementation, masking procedures, the statistical analysis plan, and the rationale for the planned sample size. No secondary outcome results or analyses are posted. The adverse-event counts contain no listed events, but the record gives limited detail about safety collection and does not report death counts. These limitations mean the registry summaries are informative as descriptive records but incomplete for judging comparative effectiveness, safety, and robustness.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Randomized Trial for Botox Urinary Incontinence — NCT00178191.
• Registry record last updated 2011-10-03; status last verified 2011-09.
• Results first posted 2009-08-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry identifies NCT00178191 as a completed randomized, double-masked, parallel trial sponsored by the University of Rochester. Enrollment was 28. The recorded start was 2005-06, and primary completion was 2008-07. The phase is listed as NA.

The three groups received 200 units of Botulinum-A toxin, 300 units of Botulinum-A toxin, or placebo. The primary outcome was episodes per day at 9 months, reported as a mean with a standard error. The arm summaries list means of 6.6, 3.52, and 8.7, with standard errors of 0.969, 0.95, and 1.52, respectively.

The registry posts one outcome measure and no analyses. It does not report a comparative estimate for the primary outcome. The safety record lists zero serious and zero other adverse events in each group; death counts are not reported in the registry record.